DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTT

Phase 3

Terminated

Conditions: Radiotherapy
Toripalimab
Sorafenib
Advanced Hepatocellular Carcinoma

Interventions: Other: Radiotherapy plus Toripalimab
Drug: Sorafenib

First Posted Date: 2021-01-14

Last Posted Date: 2025-02-26

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT04709380

Locations: 🇨🇳
Bo Chen, Beijing, Beijing, China

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

First Posted Date: 2020-12-17

Last Posted Date: 2025-05-11

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT04671303

Locations: 🇨🇳
cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Rectal Cancer

Interventions: Combination Product: Concurrent Chemoradiotherapy
Drug: XELOX
Drug: mFOLFOX
Procedure: TME

First Posted Date: 2020-09-10

Last Posted Date: 2024-03-26

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 255

Registration Number: NCT04543695

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: NSCLC

Interventions: Drug: SHR-1210
Drug: Apatinib

First Posted Date: 2020-08-10

Last Posted Date: 2020-09-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 74

Registration Number: NCT04506242

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Phase 3

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Almonertinib plus carboplatin and pemetrexed
Drug: Almonertinib

First Posted Date: 2020-08-05

Last Posted Date: 2020-08-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 460

Registration Number: NCT04500717

Locations: 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳
Peking University International Hospital, Beijing, China

and more 2 locations

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Phase 3

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Almonertinib plus carboplatin and pemetrexed
Drug: Almonertinib

First Posted Date: 2020-08-05

Last Posted Date: 2020-08-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 166

Registration Number: NCT04500704

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

and more 2 locations

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Phase 2

Conditions: HER2-negative Breast Cancer

Interventions: Drug: Nab paclitaxel
Biological: Tislelizumab
Drug: Doxorubicin
Drug: Epirubicin
Device: Cyclophosphamide

First Posted Date: 2020-08-04

Last Posted Date: 2020-09-03

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 55

Registration Number: NCT04498793

Locations: 🇨🇳
Beijing Huanxing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2

Recruiting

Conditions: Rare Tumor

Interventions: Drug: Almonertinib 110 MG
Drug: Dacomitinib 45 MG
Drug: Alectinib 150 MG
Drug: Crizotinib 250 MG
Drug: Pyrotinib 160/80 MG
Drug: Palbociclib 125mg
Drug: Vemurafenib 240 MG
Drug: Sintilimab 100MG
Drug: Niraparib 200/300 MG
Drug: Imatinib 400 MG
Drug: Atezolizumab 1680 MG

First Posted Date: 2020-06-09

Last Posted Date: 2025-02-11

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 770

Registration Number: NCT04423185

Locations: 🇨🇳
Cancer hospital Chinese Academy of Medical Sciences, Beijing, China

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Vinorelbine 40mg
Biological: Toripalimab 240mg
Drug: Cyclophosphamide 50 mg
Biological: Bevacizumab 5 mg/kg
Drug: Cisplatin
Drug: Capecitabine 500Mg Oral Tablet

First Posted Date: 2020-05-15

Last Posted Date: 2022-02-25

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 138

Registration Number: NCT04389073

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Beijing Huanxing Cancer Hospital, Beijing, Beijing, China

Chemoradiotherapy in Unresectable Esophageal Cancer

Phase 1

Recruiting

Conditions: Chemoradiotherapy
Albumin-bound Paxlitaxel
Esophageal Cancer
Unresectable Malignant Neoplasm

Interventions: Radiation: Radiotherapy
Drug: Albumin-Bound Paclitaxel
Drug: Cisplatin

First Posted Date: 2020-02-20

Last Posted Date: 2024-12-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 105

Registration Number: NCT04278287

Locations: 🇨🇳
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
🇨🇳
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy